Get started
Author

Margaux Seité

Observed name: Margaux Seite
Observed institution: OSE Immunotherapeutics (France)
OpenAlex ID: A5052078960
Abstract 910: A novel bifunctional anti-PD-1 IL-7 fusion protein to reinvigorate exhausted T cell and disarms Treg suppressive activity
2020 · Aurore Morello, Justine Durand, et al. · Cancer Research · 3
1370 Anti-PD-1/IL-7v immunocytokine favors proliferation & survival of TCF1+ stem like memory T cells and a durable in vivo efficacy in monotherapy or using combinatorial strategy
2023 · Aurore Morello, Justine Durand, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours
2026 · Marie Robert, Nuria Kotecki, et al. · European Journal of Cancer · 1
1366 Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T cells expansion and long-lasting in vivo efficacy
2022 · Aurore Morello, Margaux Seite, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
826 IL7R TME expression correlates with immunotherapy response and is associated with T-cell stemness with decreased apoptosis
2022 · Nicolas Poirier, Isabelle Girault, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
794 Long-term anti-tumor preclinical efficacy of an optimized anti PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity
2021 · Aurore morello, Margaux Seite, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Novel agonist monoclonal antibody targeting GPCR to decrease neutrophil accumulation and initiate resolution of chronic inflammation 2310040
2026 · Charles-Antoine Coupet, Charlène Trilleaud, et al. · The Journal of Immunology
1190 OSE-cytomask®, a novel CIS-demasking cytokine technology to increase therapeutic index of immunocytokine
2025 · Margaux Seite, Caroline Mary, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 3412: Cis demasking cytokine technology improves therapeutic index of immunocytokine
2025 · Caroline Mary, Margaux Seite, et al. · Cancer Research
Abstract 4070: CIS-demasking cytokine linker technology allows a selective cytokine delivery to activated immune cells while sparing others and peripheral toxicity
2024 · Aurore Morello, Caroline Mary, et al. · Cancer Research
852 Modified-epitope-based vaccine (OSE2101) combined with anti-PD-1/IL-7v bispecific antibody sustains long-lasting tumor specific antigen memory T cell response in vivo
2023 · Belarif Lyssia, Julien Taurelle, et al. · Journal for ImmunoTherapy of Cancer
PDF
1369 Abstract withdrawn
2023 · Caroline Mary, Virginie Thepenier, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 2955: Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like CD8 T cells expansion and long-lasting in vivo efficacy
2023 · Aurore Morello, Margaux Seite, et al. · Cancer Research
Abstract 692: Optimized antagonist anti-PD-1/IL-7 bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity
2021 · Aurore Morello, Justine Durand, et al. · Cancer Research
Works count: 14
Citation count: 9
H-index: 2
I10-index:
Year
Topic
Type